A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurre...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Bender, David, Sill, Michael W., Lankes, Heather A., Reyes, Henry D., Darus, Christopher J., Delmore, James E., Rotmensch, Jacob, Gray, Heidi J., Mannel, Robert S., Schilder, Jeanne M., Hunter, Mark I., McCourt, Carolyn K., Samuelson, Megan I., Leslie, Kimberly K.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4642817/
https://ncbi.nlm.nih.gov/pubmed/26186911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.018
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items